ValuEngine lowered shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) from a hold rating to a sell rating in a research report report published on Friday.

A number of other brokerages have also recently commented on ZIOP. HC Wainwright set a $10.00 target price on shares of ZIOPHARM Oncology and gave the company a buy rating in a report on Tuesday, August 1st. BidaskClub upgraded shares of ZIOPHARM Oncology from a sell rating to a hold rating in a report on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $13.17.

Shares of ZIOPHARM Oncology (NASDAQ ZIOP) traded up 3.67% during mid-day trading on Friday, hitting $6.21. 1,985,023 shares of the stock traded hands. The company’s 50-day moving average price is $5.82 and its 200 day moving average price is $6.25. ZIOPHARM Oncology has a 1-year low of $4.84 and a 1-year high of $7.88. The company’s market capitalization is $873.32 million.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. During the same quarter last year, the firm posted ($1.01) EPS. The business’s quarterly revenue was down 5.9% on a year-over-year basis. Equities research analysts forecast that ZIOPHARM Oncology will post ($0.56) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/16/ziopharm-oncology-inc-ziop-lowered-to-sell-at-valuengine.html.

Institutional investors and hedge funds have recently bought and sold shares of the company. Canada Pension Plan Investment Board purchased a new position in shares of ZIOPHARM Oncology in the 2nd quarter worth about $1,010,000. Vident Investment Advisory LLC raised its position in shares of ZIOPHARM Oncology by 20.0% in the 1st quarter. Vident Investment Advisory LLC now owns 137,976 shares of the biotechnology company’s stock worth $875,000 after purchasing an additional 22,996 shares during the last quarter. Old West Investment Management LLC purchased a new position in shares of ZIOPHARM Oncology in the 1st quarter worth about $205,000. Morgan Stanley raised its position in shares of ZIOPHARM Oncology by 19.5% in the 1st quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock worth $12,610,000 after purchasing an additional 324,774 shares during the last quarter. Finally, Teachers Advisors LLC raised its position in shares of ZIOPHARM Oncology by 8.3% in the 1st quarter. Teachers Advisors LLC now owns 214,906 shares of the biotechnology company’s stock worth $1,363,000 after purchasing an additional 16,398 shares during the last quarter. 41.94% of the stock is owned by hedge funds and other institutional investors.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Receive News & Stock Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related stocks with our FREE daily email newsletter.